Navigation Links
Randomized Study Comparing Cell Therapeutics' OPAXIO (Paclitaxel Poliglumex) and Radiotherapy to Standard of Care Temozolomide and Radiotherapy Treatment Open for Enrollment
Date:8/18/2011

leasing the paclitaxel chemotherapy.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.celltherapeutics.com/.

Sign up for email alerts and get RSS feeds at CTI's Web site, http://www.CellTherapeutics.com/investors_alert

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the trading price of CTI's securities. Specifically, the risks and uncertainties that could affect the development of OPAXIO include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general, and with OPAXIO in particular, including, without limitation, the potential failure of OPAXIO to prove safe and effective and/or less toxic and effective for the treatment of newly diagnosed high-grade malignant brain tumors such as GBM, including when combined with TMZ and RT, the potential failure of OPAXIO when combined with TMZ and RT to provide PFS and OS responses to newly-diagnosed high-grade malignant brain tumors such as GBM, that the results of the new OPAXIO study may not be positive or be used to plan a phase III study of OPAXIO for approval for use in treating newly diagnosed GBM, that CTI cannot predict or guarantee the pace of patient enrollment in the phase II clinical study comparing OPAXIO to TMZ, Brown  and CTI's ability to continue to raise capital as needed to fund its operations, competitive factors, technological developments, costs of developing, producing and selling CTI's product candidates such as OPAXIO, and the risk factors listed or described from tim
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Jennerex and Partners Present Positive JX-594 Randomized Phase 2 Clinical Data Showing Promising Survival Benefit in Patients with Advanced Liver Cancer
2. Inspire MD Announce the MASTER (MGUARD for Acute ST Elevation Reperfusion) Randomized Trial in TCT2010. Study Chairman Will be Dr. Gregg Stone
3. OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial
4. YM BioSciences enrolls first US patient in Phase II randomized, double-blind brain metastases trial for nimotuzumab
5. Aegera Therapeutics Initiates a Randomized Phase 2 Study with AEG35156 for the Treatment of Hepatocellular Carcinoma
6. Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer
7. Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans
8. Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML)
9. Harvest Technologies Announces Completion of Patient Enrollment in its Randomized, Controlled, Double Blind Multicenter IDE Non-Reconstructable Critical Limb Ischemia Trial
10. NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD & NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS
11. OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... , A major pan-European survey ... delivery of care has revealed changing trends in many ... the provision of healthcare services across the continent. The ... European Gastroenterology (UEG), have been announced today and led ... the burden of GI disorders across Europe ...
(Date:10/20/2014)... Oct. 20, 2014 PureTech , a ... big healthcare problems, announced today the closing of ... participation from Invesco Perpetual, a $120 Billion group ... drive PureTech,s existing pipeline forward and to advance ... the scientific creativity to really go for the ...
(Date:10/20/2014)... 2014 Earle Martin , ... today that Ellen Teplitzky, an experienced attorney specializing ... pharmaceutical industry, has joined the firm as Director ... services practice. NDA Partners provides legal services, ... testimony, to top law firms and their clients ...
(Date:10/19/2014)... The Latin American hardware encryption display market ... with analysis and forecast of revenue. This market was ... to reach $2,366.8 million by 2018, at a CAGR ... the TOC of the Latin American hardware encryption market ... provided. It also provides a glimpse of the segmentation ...
Breaking Biology Technology:Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 2Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6NDA Partners Appoints Ellen Teplitzky, JD as Director of its Legal Services Practice 2The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 2The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 3
... ... PDSS Leadership Award at the 3rd Annual Pacific Drug Safety Summit, which took place last ... the moderator of the event and serves as Chairman of BioSoteria,s Board of Advisors. ... Emeryville, CA (PRWEB) September 30, ...
... TOKYO, September 30 Sosei Group Corporation,("Sosei"; TSE ... of the New Drug Application (NDA) for the emergency,contraceptive ... (MHLW) by Sosei Co. Ltd., its wholly owned Japanese ... oral emergency contraceptive "morning after pill" which,is used to ...
... N.C., Sept. 29 Oxygen Biotherapeutics, Inc. (OTC ... presentation for investors by company chairman and CEO, ... website. The link to the presentation can be ... Relations section of the website at www.oxybiomed.com. It ...
Cached Biology Technology:Hugh Tilson Receives Leadership Award at Pacific Drug Safety Summit 2Hugh Tilson Receives Leadership Award at Pacific Drug Safety Summit 3
(Date:10/14/2014)... 14, 2014 – Scientists from The Scripps Research Institute ... Institutes of Health (NIH) to lead an investigation of ... disease in Africa. The study aims to understand how ... die, while others survive the inflection. , "The ... mechanism of how Lassa fever virus causes disease and ...
(Date:10/14/2014)... week, an international team of researchers, led by the ... the journal Nature Genetics a brief genomic ... varieties of the tomato plant. , The C.M. Rick ... important role in this study by providing seed of ... This study, which builds on the first tomato genome ...
(Date:10/14/2014)... Philadelphia, PA, October 14, 2014 – Over the past ... failure of institutions to meet the needs of infants ... failure of these infants to thrive. , ... the development of the cortex. A generation of research ... explore, promote cortical development and cognitive function. In contrast, ...
Breaking Biology News(10 mins):Scripps Research Institute team receives $6.6 million to investigate deadly Lassa virus 2Institutional rearing may increase risk attention-deficit disorder 2
... -- Can,t help molding some snow into a ball and ... lake as you can? New research from Indiana University and ... species on Earth, readily learn to throw long distances. This ... with language development in a way critical to our very ...
... discovered the last major element of the series of chemical ... from a protein on the surface of a plant cell ... were already known, new research from a team including Carnegie,s ... about the mechanism through which brassinosteroids cause plant genes to ...
... COLUMBIA, Mo. In an article in the Nov. ... National Academy of Science , researchers with Dow AgroSciences and ... when transformed into corn and soybeans, provide robust resistance to ... and soybean growers a solution to the growing problem of ...
Cached Biology News:IU study: Humans' critical ability to throw long distances aided by an illusion 2IU study: Humans' critical ability to throw long distances aided by an illusion 3Nailing down a crucial plant signaling system 22 bacterial enzymes confer resistanceto common herbicide, say MU researchers 2
... RNAi Kit is optimized for ... amounts of ready-to-use dsRNA for ... The MEGAscript RNAi Kit is ... transcription technol-ogy and includes reagents ...
Total Proteins from over 50 different human Alzheimer, Diabetic, Liver Cirrhosis, and Lupus diseased tissues are available....
... building blocks, Parker can create economical ... that are ideal for pick-and-place and ... Parker can also integrate pneumatic axes, ... ,guarding., Standard or custom configurations ...
... its patented technology, the Lone Wolf valve ... Normally Open proportional valve available on the ... provides repeatable high-speed performance, and ensures maximum ... , Enhances system control and patient comfort. ...
Biology Products: